Geneva, April 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600121774) titled 'A prospective, open-label, multicenter, phase II clinical study on postoperative chemotherapy combined with QL1706 for the treatment of high-risk triple-negative breast cancer' on April 2.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Condition:
Patients with triple-negative breast cancer who have lymph node metastasis after surgery
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-04-02
Target Sample Size: Intervention group:62;
Countries of Recruitment:
C...